检索结果 - Filip Callewaert

  • Showing 1 - 12 results of 12
Refine Results
  1. 1
    Skeletal sexual dimorphism: relative contribution of sex steroids, GH–IGF1, and mechanical loading

    Skeletal sexual dimorphism: relative contribution of sex steroids, GH–IGF1, and mechanical loading 由 Filip Callewaert, Mieke Sinnesael, Evelien Gielen, Steven Boonen, Dirk Vanderschueren

    出版 2010
    获取全文 获取全文
    Revisão
    加到收藏夹
    Saved in:
  2. 2
    Sexual dimorphism in cortical bone size and strength but not density is determined by independent and time-specific actions of sex steroids and IGF-1: Evidence from pubertal mouse models

    Sexual dimorphism in cortical bone size and strength but not density is determined by independent and time-specific actions of sex steroids and IGF-1: Evidence from pubertal mouse... 由 Filip Callewaert, Katrien Venken, John J. Kopchick, Antonia Torcasio, Harry van Lenthe, Steven Boonen, Dirk Vanderschueren

    出版 2009
    获取全文 获取全文
    Artigo
    加到收藏夹
    Saved in:
  3. 3
    Androgen receptor disruption increases the osteogenic response to mechanical loading in male mice

    Androgen receptor disruption increases the osteogenic response to mechanical loading in male mice 由 Filip Callewaert, Astrid D. Bakker, Jan Schrooten, Bart Van Meerbeek, Guido Verhoeven, Steven Boonen, Dirk Vanderschueren

    出版 2009
    获取全文 获取全文
    Artigo
    加到收藏夹
    Saved in:
  4. 4
    Clinical pharmacology of caplacizumab for the treatment of patients with acquired thrombotic thrombocytopenic purpura

    Clinical pharmacology of caplacizumab for the treatment of patients with acquired thrombotic thrombocytopenic purpura 由 Maria Laura Sargentini‐Maier, Philip De Decker, Claudia Tersteeg, Jan Canvin, Filip Callewaert, Hilde De Winter

    出版 2019
    获取全文 获取全文
    Revisão
    加到收藏夹
    Saved in:
  5. 5
    Androgen Signaling in Myocytes Contributes to the Maintenance of Muscle Mass and Fiber Type Regulation But Not to Muscle Strength or Fatigue

    Androgen Signaling in Myocytes Contributes to the Maintenance of Muscle Mass and Fiber Type Regulation But Not to Muscle Strength or Fatigue 由 Jill Ophoff, Karen Van Proeyen, Filip Callewaert, Karel De Gendt, Katrien De Bock, An Vanden Bosch, Guido Verhoeven, Peter Hespel, Dirk Vanderschueren

    出版 2009
    获取全文 获取全文
    Artigo
    加到收藏夹
    Saved in:
  6. 6
    Evaluation of efficacy and safety of the anti-VWF Nanobody ALX-0681 in a preclinical baboon model of acquired thrombotic thrombocytopenic purpura

    Evaluation of efficacy and safety of the anti-VWF Nanobody ALX-0681 in a preclinical baboon model of acquired thrombotic thrombocytopenic purpura 由 Filip Callewaert, Jan Roodt, Hans Ulrichts, Thomas Stöhr, Walter J. Janse van Rensburg, Seb Lamprecht, Stefaan Rossenu, Sofie Priem, Wouter Willems, Josefin-Beate Holz

    出版 2012
    获取全文 获取全文
    Artigo
    加到收藏夹
    Saved in:
  7. 7
    Caplacizumab reduces the frequency of major thromboembolic events, exacerbations and death in patients with acquired thrombotic thrombocytopenic purpura

    Caplacizumab reduces the frequency of major thromboembolic events, exacerbations and death in patients with acquired thrombotic thrombocytopenic purpura 由 Flora Peyvandi, Marie Scully, Johanna A. Kremer Hovinga, Paul Knöbl, Spero R. Cataland, Kristof De Beuf, Filip Callewaert, Hilde De Winter, Robert K. Zeldin

    出版 2017
    获取全文 获取全文
    Artigo
    加到收藏夹
    Saved in:
  8. 8
    Caplacizumab for Acquired Thrombotic Thrombocytopenic Purpura

    Caplacizumab for Acquired Thrombotic Thrombocytopenic Purpura 由 Flora Peyvandi, Marie Scully, Johanna A. Kremer Hovinga, Spero Cataland, Paul Knöbl, Haifeng Wu, Andrea Artoni, John‐Paul Westwood, Magnus Mansouri Taleghani, Bernd Jilma, Filip Callewaert, Hans Ulrichts, Christian Duby, Dominique Tersago

    出版 2016
    获取全文 获取全文
    Artigo
    加到收藏夹
    Saved in:
  9. 9
    Efficacy and safety of open‐label caplacizumab in patients with exacerbations of acquired thrombotic thrombocytopenic purpura in the HERCULES study

    Efficacy and safety of open‐label caplacizumab in patients with exacerbations of acquired thrombotic thrombocytopenic purpura in the HERCULES study 由 Paul Knoebl, Spero R. Cataland, Flora Peyvandi, Paul Coppo, Marie Scully, Johanna A. Kremer Hovinga, Ara Metjian, Javier de la Rubia, Katerina Pavenski, Jessica Minkue Mi Edou, Hilde De Winter, Filip Callewaert

    出版 2019
    获取全文 获取全文
    Artigo
    加到收藏夹
    Saved in:
  10. 10
    Caplacizumab prevents refractoriness and mortality in acquired thrombotic thrombocytopenic purpura: integrated analysis

    Caplacizumab prevents refractoriness and mortality in acquired thrombotic thrombocytopenic purpura: integrated analysis 由 Flora Peyvandi, Spero R. Cataland, Marie Scully, Paul Coppo, Paul Knoebl, Johanna A. Kremer Hovinga, Ara Metjian, Javier de la Rubia, Katerina Pavenski, Jessica Minkue Mi Edou, Hilde De Winter, Filip Callewaert

    出版 2021
    获取全文
    Artigo
    加到收藏夹
    Saved in:
  11. 11
    Caplacizumab Treatment for Acquired Thrombotic Thrombocytopenic Purpura

    Caplacizumab Treatment for Acquired Thrombotic Thrombocytopenic Purpura 由 Marie Scully, Spero R. Cataland, Flora Peyvandi, Paul Coppo, Paul Knöbl, Johanna A. Kremer Hovinga, Ara Metjian, Javier de la Rubia, Katerina Pavenski, Filip Callewaert, Debjit Biswas, Hilde De Winter, Robert K. Zeldin

    出版 2019
    获取全文 获取全文
    Artigo
    加到收藏夹
    Saved in:
  12. 12
    Long‐term follow‐up of patients treated with caplacizumab and safety and efficacy of repeat caplacizumab use: Post‐HERCULES study

    Long‐term follow‐up of patients treated with caplacizumab and safety and efficacy of repeat caplacizumab use: Post‐HERCULES study 由 Marie Scully, Javier de la Rubia, Katerina Pavenski, Ara Metjian, Paul Knöbl, Flora Peyvandi, Spero R. Cataland, Paul Coppo, Johanna A. Kremer Hovinga, Jessica Minkue Mi Edou, R. Sousa, Filip Callewaert, Sriya Gunawardena, Julie Lin

    出版 2022
    获取全文 获取全文
    Artigo
    加到收藏夹
    Saved in:

检索工具: